Sildenafil Citrate Price Trend and Forecast 2026-2027

Key Takeaways

• Sildenafil citrate prices fell through 2025, with the India benchmark easing from USD 18.63/KG in Q1 2025 to USD 15.21/KG by Q4 2025, then holding flat at USD 15.21/KG in Q1 2026.
• The steepest drop came in the third quarter, an 11 percent fall, after which the decline slowed and the market levelled off.
• The pricing series tracked here is India, a major producer and exporter of this active pharmaceutical ingredient.
• The flat finish into early 2026 suggested the market had found a floor after a year of steady erosion.
• The sildenafil citrate market forecast for the remainder of 2026 leans soft, with the projected benchmark holding in a USD 11.53 to 15.08/KG band on the available data.

What Is Sildenafil Citrate and Why Does It Matter?

Sildenafil citrate is the active pharmaceutical ingredient in a well-known vasodilator medicine. It works by relaxing blood vessels, and it is prescribed both for erectile dysfunction and, at different doses, for pulmonary arterial hypertension. As a high-volume generic ingredient, it sits in the regulated fine-chemicals bucket, where quality compliance matters as much as cost.

From a market view, sildenafil citrate matters because it underpins one of the most recognised generic drug categories in the world. With the original patents long expired, supply is competitive and broad, and India is a major source of production and export.

Because it is a mature generic ingredient, its price responds to a focused list of inputs: key intermediate and raw-material costs, producer operating rates, regulatory compliance burden, currency, and the persistent pressure of generic competition.

Which Sectors Are Driving Sildenafil Citrate Demand?

• Erectile Dysfunction Treatment: this is the dominant pull, where sildenafil is a first-line generic therapy. Demand is steady and broad-based across global markets.
• Pulmonary Hypertension Therapy: at specific doses, sildenafil treats pulmonary arterial hypertension, a smaller but clinically important and resilient source of demand.
• Generic Formulations: the bulk of volume goes into generic tablets made by formulators worldwide, keeping ingredient offtake firm and predictable.
• Regulated-Market Exports: supply to tightly regulated markets rewards compliant, well-documented material, a quality-led pocket of demand.

Global Sildenafil Citrate Price Trend in 2025

As this report tracks a single market, the global sildenafil citrate benchmark follows that series. It eased from USD 18.63/KG in Q1 2025 to USD 15.21/KG by Q4 2025, and then held steady to USD 15.21/KG in Q1 2026. The figures are taken directly from the regional data in this report, and the quarterly path is set out in the table below.

India Sildenafil Citrate Price Trend in 2025

India is a major producer and exporter of sildenafil citrate, and the tracked series showed a steady decline that levelled off. Prices held firm early, then fell through the second half before flattening into 2026, a pattern typical of a mature generic ingredient under competitive pressure.

The benchmark eased from USD 18.63/KG in Q1 2025 to USD 18.28/KG in Q2, then fell to USD 16.24/KG in Q3 and USD 15.21/KG in Q4, before holding flat at USD 15.21/KG in Q1 2026. The third quarter did most of the work, after which the market settled at its new, lower level.

What Factors Drove Sildenafil Citrate Costs in 2025?

• Generic competition. As a long-established off-patent ingredient, sildenafil faces broad, steady competition, the main force behind the year-long decline.
• Intermediate and raw-material costs. The cost of key chemical intermediates set the production floor, and softer inputs are consistent with the steady fall and the later levelling-off.
• A second-half turn. Prices held firm in the first half, then fell from the third quarter, suggesting easing input costs or fuller supply took over as the year progressed.
• Steady demand. Non-discretionary demand from erectile-dysfunction and pulmonary-hypertension treatment kept offtake firm, so the move reflected supply and competition more than consumption.
• Producer operating rates. Supply concentrated among many low-cost producers meant competitive pricing rather than scarcity drove the benchmark.
• Currency. Movements in the rupee shaped export economics and landed costs for overseas buyers.

Sildenafil Citrate Market Forecast for 2026

The sildenafil citrate market forecast for 2026 leans soft. The projected path sits at or below the level reached at the end of 2025, consistent with the steady erosion and the flat finish. The base case is a mature, competitive generic market that holds near its floor or eases a little further.

The bull case is a firming in intermediate costs that stabilises prices near the top of the projected band. The bear case is intensified competition and fuller supply, which would push the benchmark toward the lower end of the projected range.

Expected Sildenafil Citrate Price Range (remainder of 2026)

The series tracks India, a major producer and exporter, so the projected range reflects that market. The band sits at or below the recent levels, in line with the steady decline through the period.

Key Analyst Insights for the Sildenafil Citrate Market

Sildenafil citrate is a market where generic competition steadily erodes prices, and the tracked series showed exactly that before levelling off. Here is what the data shows, latest first.

• March 2026. The benchmark held near USD 15.33/KG, broadly flat as the market settled after its year-long decline.
• January 2026. Prices steadied around USD 15.17/KG, confirming the floor reached at the end of 2025.
• December 2025. The benchmark closed the year near USD 15.14/KG, having absorbed most of its decline by then.
• September 2025. Prices fell to roughly USD 15.61/KG as the second-half decline set in, the steepest part of the move.
• June 2025. The benchmark eased to about USD 17.69/KG, slipping from the firm first-half levels.
• March 2025. The series began near USD 18.65/KG, the high point from which prices steadily eased.

The data points to a mature market that repriced lower and then found a floor, driven by competition and softer intermediate costs against steady demand. With supply broad and demand non-discretionary, the direction depends mostly on input costs and the intensity of competition. The flat finish suggests a floor, though the projected range leaves room for a little further softening.

Key Takeaways for Buyers and Manufacturers

In a mature, competitive market that has eased to a floor, the priority is to avoid overcommitting while protecting supply security.

For buyers, the steady decline and flat finish shape the approach.

• Buy close to need. In a market that has eased and may soften further, frequent, smaller purchases tend to beat committing far forward.
• Watch intermediate costs. The cost of key intermediates is the clearest early signal of where prices may stabilise or ease.
• Qualify several suppliers. Approving more than one compliant source balances cost against the regulatory security a medicine demands.
• Lean on steady demand. Non-discretionary demand anchors the market, a useful guide to the underlying floor.

For manufacturers, the value sits in cost discipline and protecting regulatory standing.

• Hold the line on cost. Disciplined cost control is what protects margins when prices grind lower and then flatten.
• Protect the approvals. Maintaining regulatory standing secures premium, reliable export demand in a crowded field.
• Serve the durable demand. Steady offtake from established therapies rewards efficient, compliant capacity over the cycle.